Top

News & Events

Archive: 2017

News Archive

Genesis 2017

14 December 2017
Genesis 2017
London, UK

Read more »

14th Annual bioProcessUK Conference

29 – 30 November 2017
14th Annual bioProcessUK Conference
Cardiff, UK

Read more »

HealthEx World Forum 2017

13 - 14 November 2017
HealthEx World Forum
London, UK

Read more »

BioBeat17

9 November 2017
BioBeat17
London, UK

Read more »

BIO-Europe 2017

6 – 8 November 2017
BIO-Europe 2017
Berlin, Germany

Read more »

Dimerix Appoints Medical Advisory Board in Readiness for Phase 2b Trials

MELBOURNE, Australia - Dimerix (ASX: DXB) is pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program.

Read more »

Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of Directors

Vienna, Austria - Hookipa Biotech AG (“Hookipa”), a company pioneering an innovative class of immunotherapies for oncology and infectious diseases, today announced the appointment of Dr. Jan van de Winkel as Chairman of its Board of Directors.

Read more »

Sue Charles, Instinctif Partners’, Elected to the Board of the UK BioIndustry Association

Instinctif Partners is pleased to announce that Sue Charles, Managing Partner of its Life Sciences Practice and 30 year veteran of the biotech industry has been elected to the Board of Directors of the UK BioIndustry Association (BIA).


The results of the voting were announced at the BIA AGM yesterday, alongside four other new Board members, namely Dr Jane Dancer (F-star), Prof Jackie Hunter (Benovelent AI), Dr Kyriacos Mitrophanous (Oxford BioMedica) and Keith Thompson (Cell and Gene Therapy Catapult).

Read more »

Instinctif Partners’ Sue Charles Elected to the Board of the UK BioIndustry Association

London, UK:  Instinctif Partners is pleased to announce that Sue Charles, Managing Partner of its Life Sciences Practice and 30 year veteran of the biotech industry has been elected to the Board of Directors of the UK BioIndustry Association (BIA).

Read more »

BIA Autumn Reception 2017

12 October 2017
BIA Autumn Reception
London, UK

Read more »

UK Bioscience Forum 2017

12 October 2017
UK Bioscience Forum 2017
London, UK

Read more »

ANTRUK’s Annual Lecture 2017 - Dame Sally Davies

11 October 2017
Antibiotic Research UK’s Annual Lecture – Dame Sally Davies
London, UK

Read more »

Microbiotica Celebrates Successful First Year with Third Award Win

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been awarded UK Best Start-up Biotech at the OBN Awards, which took place at Oxford Town Hall.

Read more »

Xellia Pharmaceuticals Expands its Global Specialty Anti-infective Product Manufacturing Capabilities with a US$25m Investment in its Copenhagen Site

Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has held an official ground breaking ceremony for a new US$25 million expansion at its Copenhagen site. This site houses Xellia’s headquarters and is the Company’s largest product manufacturing plant.

Read more »

Adherium Wins 2017 OBN Award for Best Implementation of Digital Healthcare

San Mateo, CA - Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, has won ‘Best Implementation of Digital Healthcare’ at the prestigious OBN Awards 2017. The awards celebrate innovation and achievement across the UK life sciences industry and the winners were selected by an esteemed panel of judges.

Read more »

CE Marking for world’s only integrated HIV Self-Test from Atomo Diagnostics gives access to safe, accurate and reliable self-testing

Sydney, Australia - Atomo Diagnostics, a world leader in innovative point-of-care, rapid diagnostic devices, announced today that its Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body.

Read more »

Breast Cancer is the Most Feared Cancer Among Women in Germany, Although Less than Half are Aware of the Benefits of Genomic Testing

IRVINE, CA and AMSTERDAM –  Breast cancer is the most feared type of cancer among women in Germany, according to a recent representative survey commissioned by Agendia, a world leader in personalized medicine and molecular cancer diagnostics. 21% of the over 1,000 women questioned in a telephone survey carried out by KANTAR Emnid said that of all cancers, they most feared breast cancer, slightly ahead of colon and lung cancer (both at 20%). Over half (57%) of respondents said that they, or a relative or friend, have already been affected by breast cancer.

Read more »

Instinctif Partners Life Sciences Congratulates the Winners of the OBN Awards 2017

London: Instinctif Partners, the business communications consultancy, congratulates all of the winners of the OBN Awards 2017, in particular its clients Microbiotica for being awarded the ‘Best Start-up Biotech Company, and Adherium for winning the ‘Best Implementation of Digital Healthcare’. 

Read more »

Regulatory Approval in Europe Granted for Synthon’s Glatiramer Acetate 40 mg/ml

Nijmegen, the Netherlands - Synthon today announced that it has successfully concluded the decentralized procedures for glatiramer acetate 40 mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe. Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone®* 40mg.

Read more »

OBN Awards 2017

5 October 2017
OBN Awards 2017
Oxford, UK

Read more »

SkinBioTherapeutics plc: Full year results

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX or the “Company”) a life sciences company focused on skin health, has announced its full year results for the year to 30 June 2017.

Read more »

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

Tuebingen, Germany and Houston, Texas - Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million.

Read more »

SkinBioTherapeutics: SkinBiotix® platform passes external cytotoxicity tests

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, has passed third party cellular toxicity tests for its SkinBiotix® technology, confirming previous in-house observations on its safety and applicability.

The Company has also been progressing its three programmes and is on track to hit its key milestone of first studies in man in 2018.

Read more »

FierceBiotech Executive Summit- London

2 October 2017
UK Fierce Biotech Summit, Royal Society of Medicine
London, UK

Read more »

PnuVax awarded $29.4 million USD grant to advance innovative vaccine into clinical trials

Kingston, Canada – PnuVax Incorporated, an organization dedicated to the production of high quality vaccines and biopharmaceuticals for the promotion of public health worldwide, today announced that it is the recipient of a $29.4 million USD ($36 million CDN) grant. The grant will be used to further develop and clinically evaluate PnuVax’s innovative pneumococcal conjugate vaccine. Milestone payments will be received over the next three years as the vaccine progresses from process development through to biomanufacturing scale-up and proof-of-concept clinical trials.

 

Read more »

Mission Therapeutics’ Scientists Highlight Significance of Deubiquitylating Enzymes (DUBs) as Key Drug Targets

CAMBRIDGE, UK – An article entitled “Deubiquitylating enzymes (DUBs) and drug discovery: emerging opportunities” written by the drug discovery team at Mission Therapeutics was published online today in the scientific journal Nature Reviews Drug Discovery.

Read more »

Biotechs and the City Autumn

28 September 2017
Biotechs and the City Autumn
London, UK

Read more »

LNC Therapeutics raises €6.5m and reinforces its R&D in the Microbiota field

Bordeaux, France – LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, today announced that it has raised a €6.5 million Series C funding round.

Read more »

Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine® Approach in Patients with Advanced Solid Cancers

Houston, Texas and Tuebingen, Germany – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program. IMA201 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach, and is based on genetically engineering a patient’s own T-cells to express an exogenous TCR. The goal is to redirect and activate the cells to treat solid tumors. The single-center clinical study is now open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Read more »

Clinigen Group plc: Strong Performance With Adjusted EPS Up 25%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, has today published its full year results for the year ended 30 June 2017.

Read more »

Breast Cancer – Let’s Make It Personal: Agendia Supports Breast Cancer Awareness Month with International Program of Activities

IRVINE, CA and AMSTERDAM – Agendia, a world leader in personalized medicine and molecular cancer diagnostics, is supporting Breast Cancer Awareness Month with activities throughout late September and October across the United States and Europe around the theme of ‘Breast Cancer – Let’s Make It Personal’.

Read more »

17th Annual Biotech in Europe Forum

26 – 27 September 2017
17th Annual Biotech in Europe Forum
Basel, Switzerland

Read more »

Corporate & Financial Awards 2017

26 September 2017
Corporate & Financial Awards
London, UK

Read more »

Technology vs Infectious Diseases: An Imperial / Royal Institution Summit

26 September 2017
Technology vs Infectious Diseases: An Imperial / Royal Institution Summit
London, UK

Read more »

DNAe Previews its Semiconductor Genomic Analysis Test to Address the Challenge of Sepsis

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor based genomic analysis technologies, and the developer of a new, game-changing test for diagnosis of bloodstream infections that can lead to sepsis, previews its LiDia™ bloodstream infection (BSI) test today at the ‘Technology vs Infectious Diseases’ Summit held at the Royal Institution in London.

Read more »

e-Therapeutics plc: Interim Results for the 6 Months Ended 31 July 2017

Oxford, UK: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces its half year results for the six months ended 31 July 2017 (H1 17).

Read more »

Clinigen and Cumberland launch Totect® in the U.S.

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the ‘Group’), the global pharmaceutical and services company and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a U.S. specialty pharmaceutical company, announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S.

Read more »

Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022

LONDON, BOSTON, TOKYO, SAN FRANCISCO — The “EvaluateMedTech World Preview 2017, Outlook to 2022” report from life science commercial intelligence firm Evaluate Ltd, reveals Medtronic was the leading medtech company in 2016 with sales of almost $30bn and will retain the crown in 2022 with sales forecast to reach $37.7bn; Abbott to jump to 3rd place as its acquisition of St. Jude creates the world’s second largest cardiology company.

Read more »

5th Annual MedTech & Digital Health Forum

25 September 2017
5th Annual MedTech & Digital Health Forum
Basel, Switzerland

Read more »

Wear Jeans, Change Lives, Jeans for Genes Day, Friday 22 September 2017

For over 10 years Instinctif Partners has supported Jeans for Genes Day which is the annual fundraising campaign for Genetic Disorders UK, the national charity that supports individuals and families affected by a genetic disorder.


On Friday 22 September we once again left our suits at home and wore our jeans to help to raise money for this great cause – helping to fund the vital care and support services that transform the lives of 1-in-25 children who have inherited a genetic disorder that makes their life very difficult.

Read more »

Capital Cell, Europe’s First Dedicated Life Sciences Crowdfunding Platform, Opens to UK investors

Cambridge, UK – Investing in the UK’s innovative life sciences and biotech sector just became more accessible to a wide spectrum of investors, with Capital Cell, Europe’s first dedicated Life Sciences crowdfunding platform. Today Capital Cell has formally ‘opened to investors’ with the first four investment opportunities now live on the platform. These opportunities include a company developing alternatives to antibiotics and an equine health company.

Read more »

One Nucleus Network Meeting

20 September 2017
One Nucleus Network Meeting
Cambridge, UK

Read more »

Adherium Appoints New CFO

San Mateo, CA - Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today announced the appointment of Timothy A. Marcotte as its new Chief Financial Officer. Mr. Marcotte will join the Company’s leadership team and be based out of the Company’s U.S. headquarters in San Mateo, California.

Read more »

Cancer care: Key public health concern that requires EU action

The next two decades will see major increases in the cancer burden across Europe. As the costs of effective therapies keep on rising, should the EU be doing more?

Click here to read our white paper on Cancer - When healthy cells go rogue

Read more »

Abzena appoints Lotta Ljungqvist as Non-Executive Director

Cambridge, UK – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that Lotta Ljungqvist has today been appointed as a Non-Executive Director of the Company.

Read more »

Moncef Slaoui joins Medicxi

London & Geneva & Jersey – Medicxi, the leading European life sciences investment firm, today announces that Dr Moncef Slaoui, alongside his other commitments, has joined its team as Partner. Dr Slaoui was formerly GSK’s Chairman of Pharmaceutical R&D and of its vaccines division.

Read more »

Aplagon Partners with Cadila Pharmaceuticals to Develop and Commercialize APAC First-in-Class Antithrombotics for the Prevention of Blood Vessel Occlusions Related to Vascular Interventions

HELSINKI AND STOCKHOLM - Aplagon Oy (“Aplagon”) and Cadila Pharmaceuticals Sweden AB today announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury.

Read more »

Microbiotica Wins Biotech and Money’s ‘Life Science Spin-out of the Year’

Cambridge, UK, – Microbiotica, a leading player in microbiome-based therapeutics, announces that it was chosen as the winner of the ‘Life Science Spin-out of the Year’ at the recent Biotech and Money 2017 Awards.

Read more »

Microbiotica to Present at Leading Microbiome Summit

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, today announces that CEO, Dr Mike Romanos, will present at the Annual Microbiome Summit: Translating into Diagnostics and BioTherapeutics, 21-22 September, in Vienna, Austria.

Read more »

Health for Life Capital™ Participates in $35m Series B Financing of Visionary Food Science Company MycoTechnology Inc

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that, through its Health for Life Capital™ investment vehicle, it has participated in a US$35m financing of MycoTechnology, a company harnessing nature to develop unique innovative ingredients to solve some of the toughest challenges in the food and beverage industry.

Read more »

Cell Medica appoints CSO to accelerate R&D for CAR and TCR programmes

London, UK and Houston, TX - Cell Medica (or ‘the Company’), a leader in cell-based immunotherapies for the treatment of cancer, today announced the appointment of Luis Borges, PhD, as Chief Scientific Officer. Luis will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including senior positions at Five Prime Therapeutics and Amgen, where he played a senior role in the discovery and development of several blockbuster drugs and therapeutic candidate molecules.

 

Read more »

Instinctif Partners’ Sue Charles Standing for Election for BioIndustry Association Board

London, UK:  Instinctif Partners is pleased to announce that Sue Charles, Managing Partner of its Life Sciences Practice and 30 year veteran of the biotech industry is standing for election for the BioIndustry Association (BIA) Board of Directors.

Read more »

Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial

Oxfordshire, UK – Karus Therapeutics Ltd (‘Karus’), a leader in the design and development of innovative medicines with breakthrough potential in the treatment of cancer, today announced that the first patients have been dosed with its histone deacetylase 6 (HDAC6) inhibitor, KA2507, in a Phase I clinical study. This is the Company’s second orally-active small molecule cancer therapeutic agent to enter clinical trials during the past 12 months.

Read more »

Instinctif Partners Congratulates Winners of Biotech and Money Annual Awards 2017

London, UK: Instinctif Partners, the business communications consultancy, congratulates all of the winners of the Biotech and Money Awards 2017, in particular its clients Microbiota and F-Star for winning awards.

Read more »

2017 Biotech and Money Assembly and Awards Gala Dinner

14 September 2017
2017 Biotech and Money Assembly and Awards Gala Dinner
London, UK

Read more »

Nordic Life Science Days 2017

12 – 14 September 2017
Nordic Life Science Days
Malmö – Copenhagen

Read more »

Levicept Starts First-in-Human Phase I Trial of LEVI-04, A Novel Fusion Protein Therapy for Chronic Pain

Sandwich, UK – Levicept Ltd., an asset-centric biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces that it has commenced its Phase I trial of LEVI-04 in healthy volunteers and osteoarthritis patients at Hammersmith Medical Research, London UK.

Read more »

European Patent Office Decides in Synthon’s Favor in Glatiramer Patent Case

Nijmegen, the Netherlands- Yesterday, in opposition proceedings filed by inter alia Synthon, the Technical Board of Appeal (TBA) of the European Patent Office revoked the last of Teva's three glatiramer so-called HBr patents which claimed an allegedly improved process for the synthesis of glatiramer acetate.

Read more »

DNAe Presents Pipeline of Rapid Diagnostic Tests Set to Bring Next Generation Sequencing Closer to the Clinical Point-Of-Need

London, UK and Carlsbad, CA, USA – DNAe, the inventor of next generation semiconductor DNA sequencing technology and developer of a new, game-changing test for bloodstream infections, announces that its CBO, Nick McCooke presented an update on its first product, the LiDia™ bloodstream infections (BSI) test, and outlined DNAe’s pipeline of genomic-based tests at BioCentury’s 24th Annual Newsmakers in the Biotech Industry. The conference took place on the 8th September 2017 in New York.

Read more »

Invicro Acquires Imanova to Expand Global Imaging Capabilities

Boston, MA, USA, Invicro, LLC, a leading provider of imaging services and software for research and drug development, announced today the acquisition of UK-based Imanova. Invicro and Imanova will merge all activities to establish the world’s largest provider of translational imaging services and analytics from pre-clinical development through to late-phase clinical trials.

Read more »

10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint® in Personalizing Early-Stage Breast Cancer Treatment

Irvine, Calif. & Amsterdam- Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces three important studies presented at the 2017 ESMO Congress in Madrid earlier this week.

Read more »

Recommended Acquisition Of Quantum Pharma plc by Clinigen Group plc

Clinigen Group plc (AIM: CLIN, "Clinigen") and Quantum Pharma Plc (AIM: QP, "Quantum") have agreed terms of a recommended acquisition by Clinigen of the entire issued and to be issued share capital of Quantum for £150.3 million, to be effected by means of a scheme of arrangement.

Read more »

Scientists Present Positive Progress in the Development of a New Class of Broad-Spectrum Organogold Antibiotics to Address Antibiotic-Resistant Bacterial Infections

Cambridge, UK and Stevenage, UK - Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the growing threat of resistance to antibiotics.

Read more »

Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler

Adherium Limited, a digital health company that improves medication adherence and patient outcomes, today announced it has released SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology, for AstraZeneca’s Turbuhaler medication.

Read more »

Recce Confirms Pre-IND Data Submission to US FDA for its Lead Antibiotic Candidate

SYDNEY Australia: Recce Limited (ASX: RCE), a pre-clinical stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today confirmed it has submitted pre-clinical data and related documentation to the US Food & Drug Administration (FDA) as part of the process for its application to enter human clinical trials for its lead candidate antibiotic, RECCE® 327.

Read more »

Congenica’s Sapientia™ selected by Coimbra Paediatric Hospital for Portugal’s In2Genome Genetic Disease Diagnosis Project

Cambridge, UK – Congenica, a global provider of clinical genomics interpretation software, today announced a new customer partnership with the Coimbra Paediatric Hospital (CPH), a leading paediatric hospital in Portugal and part of the Coimbra Hospital and University Centre (CHUC). Through this partnership, the hospital has licensed Congenica’s Sapientia™ software platform to perform analysis of whole-exome sequencing data and produce diagnostic reports for its In2Genome project. The €1.2 million ($1.4 million) project funded by Portugal2020, Compete 2020, and European Structural and Investment, aims to revolutionize the diagnosis of rare genetic diseases through insights gained from population-wide genomic data.

Read more »

DNAe to Present its NGS Diagnostics Pipeline at 24th Annual Newsmakers in the Biotech Industry

DNAe, the inventor of semiconductor DNA sequencing technology and developer of a new, game-changing test for bloodstream infections, announces that its Chief Business Officer, Nick McCooke will present an update on its first product, the LiDia™ bloodstream infections (BSI) test, at BioCentury’s 24th Annual Newsmakers in the Biotech Industry on 8th September in New York. DNAe will also outline its pipeline of diagnostic tests, including applications in sepsis, antibiotic resistant infections, flu and cancer.

Read more »

Dimerix Announces DMX-200 Tablet Manufacture and Human Pharmacokinetic Study Timeline

Dimerix Limited (ASX: DXB), is pleased to announce that manufacturing has been scheduled for later this month to produce the extended release tablet of propagermanium which will be used in the Company’s DMX-200 human pharmacokinetic study and Phase 2b trial in Chronic Kidney Disease.

Read more »

Adherium Receives U.S. 510(K) Clearance for Next Generation Smartinhaler for AstraZeneca’s Symbicort Aerosol Inhaler

Melbourne, Australia: Adherium Limited (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(K) clearance for its new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler.

Read more »

Adherium Exhibiting at 27th International Congress of the European Respiratory Society

Adherium Limited (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, will be exhibiting at the 27th International Congress of the European Respiratory Society (ERS), being held at the MiCo Milano Congressi in Milan, Italy, from 9-13 September 2017.

Read more »

Imugene Commences First Patient Dosing of HER-Vaxx

Imugene Limited (ASX: IMU), an immunooncology company is pleased to announce it has commenced first patient dosing of the Phase 1b/2 clinical study of its HER-Vaxx immunotherapy in gastric cancer. Patients are currently being enrolled at eight key cancer hospital sites in Asia, including Hong Kong, Thailand and Taiwan.

Read more »

How the UK Life Sciences Industry Post-Brexit Can be World-Leading

The UK Government’s Industrial Strategy Green Paper has named the life sciences as a key strategic sector. Today, the findings of an independent sector-led review into the £64 billion life sciences sector was unveiled, which will inform the basis of UK Government work with the sector towards a sector deal in the coming months. This report comes at a critical time as the UK is defining its post Brexit strategies.

The Life Science Industrial Strategy (LSIS) report to Government lays out a consensus of the opportunity across the life science ecosystem in the UK. Its development was led by Professor Sir John Bell and the Life Sciences Industrial Strategy Board which was established in 2016.

Read more »

Xellia Pharmaceuticals Completes Expansion of its Budapest Facilities, Strengthening its Global Anti-infective Product Capabilities

Copenhagen, Denmark, and Budapest, Hungary, 22 August 2017 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has completed the expansion of its new US$13m, Centralized Laboratory Services building at its Budapest manufacturing site. The expansion strengthens Xellia’s global anti-infective product capabilities with additional product stability and release testing expertise and capabilities.

Read more »

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA101 phase I trial is the first industry-sponsored trial using products consisting of autologous cytotoxic T lymphocytes targeting defined tumor antigens using Immatics’ novel and proprietary target warehouse. This single-center study is now open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Read more »

Adherium Hits 100,000 Smartinhaler™ Commercial Milestone

Melbourne, Australia- Adherium Limited (ASX:ADR), a digital health company that improves patient medication adherence and health outcomes, has recently manufactured and sold it’s 100,000th Smartinhaler™.

Read more »

Dimerix to Present Analysis of DMX-200 Phase 2a Clinical Trial in Chronic Kidney Disease at the American Society of Nephrology (ASN) Annual Kidney Week 2017

Dimerix Limited (ASX: DXB), is pleased to announce that a detailed analysis of the data from the DMX-200 Phase 2a clinical trial in Chronic Kidney Disease will be announced to the ASX coincident with its feature as a poster presentation at the American Society of Nephrology (ASN) Kidney Week 2017, to be held in New Orleans, Louisiana from October 31 to November 5, 2017.

Read more »

One Nucleus Summer Networking Meeting, Cambridge

16 August 2017
One Nucleus Summer Networking Meeting, Cambridge
Cambridge, UK

Read more »

Biotech and Money Awards 2017

Instinctif Partners was delighted to be on the Biotech and Money Advisory Board and 2017 Awards executive judging panel in June - looking forward to the Awards Gala Dinner on the 14 September at the Gibson Hall, London.

Good luck to all the finalists, including our clients Abzena, Apollo Therapeutics, Astex Pharmaceuticals, Auspherix, Cell Medica, Clinigen, Congenica, Crescendo Biologics, F-Star, Microbiotica, Mission Therapeutics and SkinBioTherapeutics.

It’s not too late to vote - online voting, which contributes to 50% of the final vote is open here.

Read more »

Clinigen Receives EC Approval for Updates to Cardioxane Product Information

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that its Commercial Medicines operation received a European Commission (EC) approval to update the current product information for Cardioxane.

Read more »

Biopharma Stages a Strong Recovery Over the First Half Even as M&A deals Disappoint, While Unprecedented Amounts of Money Flow in Medtech but Not Towards Smaller Innovators

LONDON, BOSTON, SAN FRANCISCO, TOKYO - Today EP Vantage, the independent news and analysis arm of Evaluate Ltd, releases its 2017  half-year reports on pharma & biotech and medtech sector performance.  Report authors Elizabeth Cairns and Jon Gardner provide their expert viewpoints, powered by Evaluate data and consensus forecasts.

Read more »

Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)

LONDON, BOSTON, SAN FRANCISCO, TOKYO — According to life science commercial intelligence firm, Evaluate, the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.

Read more »

Recce Confirms Delivery by Intravenous Drip for its RECCE® 327 Antibiotic, with FDA IND Submission on Track

Sydney, Australia - Recce Limited (ASX: RCE), a pre-clinical stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today confirmed it remains on track to submit its Investigative New Drug Application (IND) to the US Food and Drug Administration (FDA) for its lead compound RECCE® 327, following additional positive pre-clinical study data on mode of administration, drug clearance, dosing and efficacy.

Read more »

BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support BioScience Managers’ and Downing’s Life Sciences Investments

London, UK and Melbourne, Australia Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers) announces today that it has appointed Elizabeth Klein as an Investment Consultant, to facilitate BioScience Managers’ UK investment deal flow, in particular to support its collaboration entered into in December 2016 with London-based investment firm Downing LLP. Her primary focus will be on sourcing and reviewing investment opportunities for BioScience Managers’ and the Downing FOUR Healthcare Share Class Venture Capital Trust (VCT) plc (Downing FOUR Healthcare).

Read more »

Instinctif Partners Life Sciences Congratulates the Finalists for the 2017 OBN Awards

Instinctif Partners, the business communications consultancy, congratulates all of the nominees shortlisted as finalists for the OBN Awards 2017.

Congratulations goes to the four clients of Instinctif Partners Life Sciences’ practice across the nine award categories who have been selected as finalists.

 

Read more »

Instinctif Partners Life Sciences Congratulates the Finalists for the OBN Awards 2017

London: Instinctif Partners, the business communications consultancy, congratulates all of the nominees shortlisted as finalists for the OBN Awards 2017.

Read more »

Instinctif Partners Becomes Latest Partner of One Nucleus

Instinctif Partners has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.

Read more »

e-Therapeutics Announces Outcome of Strategic Review and Future Plans

Oxford, UK, e-Therapeutics plc (AIM: ETX):  Upon the completion of Ray Barlow’s first three months as CEO of e-Therapeutics, the Company outlines below the conclusion of the strategic review for its investors and other stakeholders.

Read more »

Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In

LONDON, BOSTON, SAN FRANCISCO, TOKYO — Today life science commercial intelligence leader, Evaluate, released case studies highlighting the value of granular patient segmentation and epidemiological data to support commercial valuations, whitespace identification and product differentiation ultimately leading to enhanced portfolio decision-making. Therapy areas covered include: CAR-T, MPS-III and Age-related Macular Degeneration.

Read more »

Recce achieves milestone with volume production of antibiotic compounds to support clinical trials

SYDNEY, Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced its new automated manufacturing facility in Sydney is now producing at name-plate standard its antibiotic compounds at volumes in preparation for human clinical trials.

Read more »

Clinigen and Sarepta Therapeutics launch a Managed Access Program to treat patients with Duchenne Muscular Dystrophy amenable to exon 51 skipping

Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access division and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have initiated a Managed Access Program (MAP) for eteplirsen in certain geographies to treat Duchenne Muscular Dystrophy (DMD) patients amenable to exon 51 skipping. This MAP (also known as an early / expanded access, or named patient program) provides a mechanism through which physicians can legally and ethically prescribe eteplirsen to patients who meet pre-specified medical criteria and where funding can be secured.

Read more »

Abzena and Telix sign licence agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Cambridge, UK and Melbourne, Australia – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Telix Pharmaceuticals Limited (‘Telix’), a biopharmaceutical company specializing in the development and commercialisation of radiopharmaceuticals for diagnostic (imaging) and therapeutic use (the “Agreement”).

Read more »

Clinigen Group plc: Year end trading update 2017

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides a trading update for the 12 months ended 30 June 2017.

Read more »

ON Helix 2017

13 July 2017
On Helix 2017
Cambridge, UK

Read more »

Rapid, Near-patient Genomic Tests for Infectious Disease set to Revolutionize Antibiotic Prescribing and Patient Care

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventor of semiconductor DNA sequencing technology and developer of a new, revolutionary sample-to-result diagnostic platform to rapidly determine the causative agent of infectious diseases, provided an update on its LiDia™ test for serious bloodstream infections (BSI), a condition which can lead to the potentially life-threatening complication of sepsis if not diagnosed and treated quickly. The test is on track for commercial launch in 2018.

Read more »

Dimerix Reports Positive Results from Phase 2a Trial of DMX-200 in Chronic Kidney Disease

MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company today announced positive safety and efficacy data (primary endpoint met) following its now completed 27 patient Phase 2a Proof of Concept, Dose Escalation Study in Chronic Kidney Disease (CKD) for lead program, DMX-200. Dimerix will now progress with the design for the planned Phase 2b DMX-200 study.

Read more »

Health for Life Capital™ Participates in Financing of Two Connected Health companies: Machtfit in Germany and Push Doctor in the UK

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, today announces that it has participated in two financing rounds in Machtfit and Push Doctor, both companies specialising in connected health, reflecting the growth potential in this innovative area. The investments were made from Seventure’s Health for Life Capital™ investment vehicle.

Read more »

Agendia’s MammaPrint® Recommended by ASCO Breast Cancer Guideline in Focused Update Based on Landmark MINDACT Trial Data

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Society of Clinical Oncology (ASCO®) has today published revised early-stage breast cancer guidelines in the Journal of Clinical Oncology, titled The Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early Stage Invasive Breast Cancer: American Society of Clinical Oncology Practice Guideline.

Read more »

Abzena and OBI Pharma sign ThioBridge™ licence agreement

Cambridge, UK, Taipei, Taiwan – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement and a master services and clinical supply agreement with OBI Pharma, a Taiwanese biopharmaceutical company (‘OBI’, TPEx: 4174).

Read more »

Clinigen and Cumberland Pharmaceuticals obtain FDA approval for Totect® in the U.S.

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the ‘Group’), the global pharmaceutical and services company and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a U.S. specialty pharmaceutical company, today announce they have obtained FDA approval for Totect® (dexrazoxane hydrochloride) in the U.S.

Read more »

Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted AUT00206 an Orphan Drug Designation for the treatment of Fragile X Syndrome, the most common known cause of inherited learning disabilities.

Read more »

OBN Summer Drinks Party – 20th Anniversary Celebration

6 July 2017
OBN Summer Drinks Party – 20th Anniversary Celebration
London, UK

Read more »

BIA Summer Networking Reception 2017

6 July 2017
BIA Summer Networking Reception
London, UK

Read more »

Agendia’s MammaPrint® recommended by the 2017 St. Gallen International Breast Cancer Guidelines in significant update

IRVINE, CA and AMSTERDAM - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the 15th St. Gallen International Breast Cancer Guidelines recently published in Annals of Oncology have recommended the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test for the third time to help guide treatment decision-making for patients with early-stage breast cancer.

Read more »

Health for Life Capital™ Participates in $13.2m Financing of Japanese Microbiome Leader Anaeropharma Science

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that it has participated in a $13.1m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventure’s Health for Life Capital™ investment vehicle.

Read more »

MammaPrint® Late Recurrence (20yr) Low Risk result identifies breast cancer patients with 97% survival at 20-years with limited endocrine therapy treatment

IRVINE, Calif. & AMSTERDAM - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics announces new data published today in JAMA Oncology.1 Following the retrospective analysis and 20-year follow-up data from the prospective, randomized Stockholm Tamoxifen Trial, a Late Recurrence (20yr) Low Risk result (referred to as the ‘indolent’ threshold in the study) of the MammaPrint® Test has demonstrated the ability to identify a sub-group of patients with exceedingly low metastatic risk 20 years after diagnosis. These patients, of which a majority only received two years of hormonal therapy, had an observed 20-year breast cancer specific survival of 97%.

Read more »

BELS Summer Reception

28 June 2017
BELS Summer Reception
London, UK

Read more »

Health for Life Capital™ Further Expands Israeli Portfolio with Investment in Microbiome App Developer

Paris, France - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that it has invested in Israel-based personalized nutrition microbiome app company DayTwo through its Health for Life Capital™ investment vehicle, as part of a $12m series A fundraising.

Read more »

Mission Therapeutics Appoints Scientific Advisory Board

Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB).
 

Read more »

BioGeneration Ventures Fund III Secures EUR 66m, exceeding EUR 50m target

Naarden, The Netherlands – BioGeneration Ventures (BGV), the early stage life sciences venture capital firm with funds focussed on European biotechnology companies, announces today an investment by the European Investment Fund (EIF) and other new investors in BGV III, taking the total capital commitments to EUR 66m, out of a maximum EUR 75m. The Fund is supported by the “InnovFin – EU Finance for Innovators” initiative under Horizon 2020 and the European Fund for Strategic Investments.

Read more »

Microbiotica Shortlisted for Biotech and Money’s ‘Life Science Spin-out of the Year’

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, is delighted to announce that it has been shortlisted for the ‘Life Science Spin-out of the Year’ category of the Biotech and Money 2017 Awards.

Read more »

Abcam announces first international Epigenetics conference in South Korea

Cambridge, UK – Abcam plc, a global leader in the supply of innovative life science reagents and tools, today announced its upcoming international conference “Epigenetic Regulatory Pathways”, to be held in Seoul, South Korea, from 26-28 June 2017. Korean and international experts will present their latest research on epigenetic disease pathways, as well as insights on related drug discovery and development.

Read more »

Prism Series launches a new era in innovation: taking down barriers and applying real solutions to healthcare challenges

London – To explore how we can use innovation to solve some of the most pressing problems in healthcare, over 150 economists, inventors, engineers, scientists, business leaders and life sciences commentators assembled at the inaugural PRISM event held at the London School of Economics on Thursday 15 June 2017.

Read more »

Clinigen signs exclusive supply agreements in Global Access

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that its Idis Global Access (‘Idis GA’) division, has signed three further exclusive agreements to manage the supply and distribution of critical medicines on demand.

Read more »

Recce Constructs Automated Manufacturing Facility to Support Clinical Trials

Syndey, Australia - Recce Limited (ASX: RCE), a pre-clinical stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced it has completed construction of a wholly owned production facility in Macquarie Park Sydney with expected outputs capable of supporting RECCE® 327 through both Phase 1 and Phase 2 human trials.

Read more »

Beijing 4P Health Research Institute initiates China’s “100K Wellness Pioneer Project” using UniteGen and Sapientia™ integrated platform

Cambridge, UK - Congenica’s Sapientia™ clinical genome analysis software platform will be used by China-based UniteGen to carry out whole genome sequencing (WGS) processing and analysis as part of China’s “100K Wellness Pioneer Project”, hosted by Beijing 4P Health Research Institute.

Read more »

Microbiotica to Present at Microbiome Drug Development Summit

Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, announces that its Chief Scientific Officer Dr Trevor Lawley will present at this year’s Microbiome Drug Development Summit, 27-29 June in Boston.

Read more »

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult

London – Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. Financial terms were not disclosed.

Read more »

Instinctif Partners Congratulates Clive Cookson on Winning the “Mediscience Media Commentator of the Year” Award 2017

London, UK: Instinctif Partners, the business communications consultancy, is pleased to congratulate Clive Cookson, Science Editor of The Financial Times for winning the ‘Mediscience Media Commentator of the Year’ at the European Mediscience Awards on 15th June 2017, in recognition of his long-standing exemplary commentary on the Life Sciences Sector.

Read more »

Recce Secures up to A$6.05 Million Investment Agreement with US Institutional Investor

SYDNEY, Australia -  Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, today announced it had entered an agreement for a flexible funding commitment of up to A$6.05 million with The Australian Special Opportunity Fund LP (ASOF), providing capital to support Recce’s synthetic antibiotic through its Investigative New Drug (IND) Application to the Food and Drug Administration in the USA and Phase I clinical trials.

Read more »

European Mediscience Awards Dinner 2017

15 June 2017
European Mediscience Awards 2017
London, UK

Table Host: Melanie Toyne Sewell

Read more »

The PRISM Series

15 June 2015
The PRISM Series
London, UK

Read more »

LifeArc set to transform medical research landscape

London - LifeArc, the UK medical research charity previously known as MRC Technology1, today announced ambitious plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research. By investing up to £500 million2 over the next five years, LifeArc will seek to generate, fund and champion innovations in antimicrobials, neuroscience, personalised oncology and respiratory medicine.

Read more »

Medicxi launches first $300m late-stage life sciences fund Medicxi Growth 1 (MG1), backed by Novartis and Verily

London & Geneva & Jersey – Medicxi today announces the close of Medicxi Growth 1 (MG1), a new $300 million fund that will focus on growth stage companies in European life sciences.
With this new late stage fund, Medicxi will help fill a clear gap in Europe, where talented life sciences entrepreneurs do not have access to as much local financial support as their US-based counterparts to expand exciting opportunities into more mature companies.

Read more »

BIA Women in Biotech Networking Evening

14 June 2017
BIA Women in Biotech Networking Evening
London, UK

Read more »

Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), a company developing highly potent and differentiated Humabody® therapeutics, today announced that Edward J. “Tad” Stewart has joined the company as Chief Business Officer.

Read more »

Three New Studies Presented at ASCO Annual Meeting Demonstrate Benefits of MammaPrint® in Aiding Individualized Treatment Management for Early-Stage Breast Cancer Patients

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced further details on three studies presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago earlier this week. These studies further demonstrate the clinical utility of Agendia’s MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test.

Read more »

Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues

Cambridge, UK, 13 June 2017 - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2017.

Read more »

‘Microbes and Me’ - how our understanding of the microbiome is pushing new horizons in research and spawning a US$0.5bn+ industry

Paris, France – 13 June 2017 – Rapidly advancing understanding of the relationship between humans and their symbiotic microbes, and how their imbalance (dysbiosis) triggers or contributes to diseases will transform opportunities for novel nutritional, diagnostic and therapeutic products, says a new report by Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector.

Read more »

Research published in Scientific Reports uses state-of-the-art CRISPR technology to validate relevance of the Dimerix Receptor-HIT technology in real time

MELBOURNE, Australia, 13 June 2017: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology today announced the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports (1).

Read more »

Instinctif Partners Life Sciences Congratulates the Shortlisted Nominees for the Biotech & Money Awards 2017

London: Instinctif Partners, the business communications consultancy, congratulates all of the nominees shortlisted as finalists for the Biotech & Money Awards 2017.

Read more »

Adherium Appoints New CEO to Drive Global Growth

Melbourne, Australia - Adherium Limited (ASX : ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of Arik Anderson as Group Chief Executive Officer (CEO). Founder and past Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the next and important phase of Adherium’s global business growth, allowing him to focus on new areas of development while Mr Anderson focusses on the global business opportunities in front of the Company today.

Read more »

Labiotech Refresh Berlin

8 June 2017
Labiotech Refresh Berlin
Berlin, Germany

Read more »

Dimerix hosts US key opinion leader meeting with NephCure Kidney International focused on development path of DMX-200 in kidney disease

MELBOURNE, Australia, 6th June 2017: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology said it has hosted a half-day meeting on Saturday 3 June 2017 in Baltimore, Maryland United States, with representatives from the patient advocacy group NephCure Kidney International and leading nephrologists from the US and Canada with representation from NephCure’s scientific advisory board and the NephCure Accelerating Cures Institute (NACI).

Read more »

F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology

Cambridge, UK – F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology antibodies.

Read more »

3rd Annual Immuno-Oncology: BD&L and Investment Forum

2 June 2017
3rd Annual Immuno-Oncology: BD&L and Investment Forum
Chicago, USA

Read more »

The PD-1 / PD-L1 Combination Therapies Revolution: New EP Vantage Report Sees Immuno-oncology Trials Triple and Keytruda Steal the Crown from Opdivo

LONDON, UK,  BOSTON, TOKYO – The battle to find a cure for cancer has led to an explosion in the number of clinical trials using anti-PD-1 and anti-PD-L1 antibodies combined with other therapeutic approaches, says a new report by EP Vantage, the wholly independent editorial arm of Evaluate, the trusted provider of life science commercial intelligence.

Read more »

Atomo Diagnostics’ HIV Self Test receives approval from Kenya Ministry of Health

Sydney, Australia - Multi-award winning medical device innovator Atomo Diagnostics today announced its pioneering HIV self test product has been approved for sale in Kenya.

Read more »

Hookipa Biotech Announces Nature Communications Publication Showing TheraT® Turns Cold Tumors Hot

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces publication in leading peer-reviewed publication Nature Communications of research data in a transgenic mouse model showing how its replicating viral vector platform TheraT® delivers potent innate immune activation including key alarmin signals.

Read more »

Bioverativ to acquire True North Therapeutics and the Abzena Inside portfolio product, TNT009

Cambridge, UK, 24 May 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, notes the announcement from Bioverativ Inc. (NASDAQ: BIVV), that it has entered into a definitive agreement to acquire True North Therapeutics for an upfront payment of $400 million plus assumed cash. True North investors are also eligible to receive additional payments of up to $425 million contingent on the achievement of future development, regulatory and sales milestones.

Read more »

SkinBioTherapeutics: Extension of research contract with University of Manchester

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company’s Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company’s ability to develop its SkinBiotix® platform.

Read more »

BioEquity Europe

22 - 23 May 2017
BioEquity Europe
Paris, France

Read more »

Clinigen achieves positive CHMP opinion concerning Cardioxane in Europe

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that its Specialty Pharma (SP) division has achieved a positive CHMP opinion in Europe to modify the current product information for Cardioxane.  It is expected that the European Commission (EC) will accept the CHMP opinion and will issue its approval later this year. This is a significant step forward in the assessment of the regulatory application which should ultimately allow physicians to consider use in paediatric patients where high dose anthracycline therapy is planned.

Read more »

Recce moves closer to clinical study application with additional data on its novel antibiotic

SYDNEY Australia 19 May 2017: Recce Limited (ASX: RCE), a preclinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotic, today announced new data on its lead compound RECCE® 327, essential for its pending data package for an Investigational New Drug (IND) application to the US Food & Drug Administration (FDA), including successful chemical analysis and structural confirmation of the candidate antibiotic, and its micro-detection in animal blood samples.

Read more »

DNAe’s Semiconductor DNA Analysis Technology Featured in Nature’s Scientific Reports’ Top 100 Most Read Papers of 2016

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventor of semiconductor DNA sequencing technology and developer of a new, revolutionary blood-to-result test for bloodstream infections, announces that an article on research utilizing the Company’s patented semiconductor DNA analysis technology has achieved recognition as one of the top 100 read articles for 2016 in Scientific Reports, a peer reviewed journal from the publishers of Nature.

Read more »

Health for Life Capital™ Expands Portfolio into Israel, Invests in Microbiome Therapeutics Company BiomX

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that, as part of a syndicate, it invests €3 million in Israeli microbiome therapeutics company BiomX (formerly called MBCure) through its Health for Life Capital™ investment vehicle. It is the first time that Seventure Partners has invested in an Israeli life sciences company.

Read more »

Autifony Therapeutics initiates recruitment into schizophrenia clinical trial for first-in-class drug

Stevenage, UK – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced the start of a Phase Ib biomarker study of the effect of AUT00206, a first-in-class Kv3 ion channel modulator, on patients with schizophrenia.

Read more »

Flexible Amersham™ Typhoon™ NIR Plus Biomolecular Imager for near-infrared multiplex detection

16 May 2017 – Amersham™ Typhoon™ NIR Plus is the latest modular and upgradable near-infrared imaging system from GE Healthcare’s Life Sciences business. NIR Plus’ three-laser flexible configuration provides two essential NIR channels, as well as a third visible laser channel for triplex protein detection to facilitate normalization and the reduction of blot-to-blot variation, saving valuable research time.

Read more »

Seventure Partners Life Sciences, Microbiome Investing Update for January – May 2017

Paris, France – 16 May 2017 - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for January – May 2017.

Read more »

Instinctif Partners Congratulates the Shortlisted Nominees for the European Mediscience Awards 2017

London, UK: Instinctif Partners, the business communications consultancy, congratulates all of the nominees shortlisted as finalists for the European Mediscience Awards 2017, especially those individuals and companies in the category, Mediscience Commentator of the Year, of which Instinctif Partners is the sponsor, for the ninth year.

Read more »

Clinigen and TESARO partner to initiate European Managed Access Program for niraparib for patients with recurrent ovarian cancer

Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access division and TESARO Inc. (NASDAQ: TSRO) have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe for the investigational PARP 1/2 inhibitor, niraparib, for patients with recurrent ovarian cancer.

Read more »

biotrinity 2017

8 – 10 May 2017
Biotrinity 2017
London, UK

Read more »

Lonza Poster detailing i-body expression in yeast

Melbourne, Australia - AdAlta Limited (ASX: 1AD), the biotechnology Company advancing its lead i-body candidate towards clinical development, announces that contract manufacturer Lonza has presented data on the production of AdAlta’s i-bodies in Lonza’s XS™ Pichia (or yeast) Expression Technology. The data was presented at the 9th Conference on Recombinant Protein Production in Dubrovnik, Croatia.

Read more »

Join the party – let’s back ambition and celebrate Britain’s success in Biotech

Britain might not have produced any large new biotech enterprises like America’s Amgen, Biogen or Gilead, but there are notable successes for which the country should be proud.  It is against these which entrepreneurs and managers of today’s biotech companies should set their ambitions and measure their success.

It’s all too easy to look to failures – of markets, Government interventions and companies - indeed this was the theme in the book Science, the State and the City: Britain's Struggle to Succeed in Biotechnology by Geoffrey Owen and Michael M. Hopkins published last year. Based on a rich analysis of the UK’s last 40 years of investment in biotech, they concluded that the UK has not succeeded in creating Bellweathers – as measured in terms of UK stock market valuations of therapeutic biotechs.

Read more »

Hookipa Biotech presents positive data from Phase 1 first-in-human trial of vaccine against cytomegalovirus

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today presented the un-blinded safety and immunogenicity data through month four from the Company’s phase 1 first-in-human trial of HB-101, a vaccine against human cytomegalovirus (CMV), based on Hookipa's proprietary Vaxwave® platform. The data was presented at the CMV 2017 Conference (www.cmv2017.nl/home) in Leeuwenhorst, The Netherlands. Further follow-up safety and immunogenicity results through month 12 of the study are expected in November 2017.

Read more »

Agendia’s MammaPrint® Now Included in First Coast Coverage for Medicare Breast Cancer Patients in Florida, Puerto Rico and the Virgin Islands

Irvine, Calif. & Amsterdam - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that First Coast Service Options Inc. (“First Coast”), the Medicare contractor for Florida, Puerto Rico, and the Virgin Islands, has revised its Local Coverage Determination (LCD-L33586) for gene expression profiling panel for use in the management of breast cancer treatment to include the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test. The MammaPrint test is intended to assess a patient’s risk for distant metastasis within 5 years.

Read more »

Congenica completes Series B financing round with investments from China-based BGI, Healthlink and Future Planet

Cambridge, UK – Congenica, a world leader in clinical genomics software for inherited diseases, today announced completion of its recently announced Series B funding round with additional investments from new strategically important investors BGI Genomics (BGI), a recognized global leader in genomics, Healthlink Capital (Healthlink), another well-established China-based life-science investor and Future Planet Capital, a global innovation fund.

Read more »

Adherium presents its Smartinhaler™ data at Respiratory Drug Delivery Europe 2017

Melbourne, Australia - Adherium Limited (ASX: ADR, ‘Adherium’), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, will today present data on its proprietary Smartinhaler™ platform at the Respiratory Drug Delivery Europe conference 2017 (RDD Europe).

Read more »

Abzena to pursue $12 million investment program to upgrade and expand its San Diego biomanufacturing operations

San Diego CA, USA – Abzena intends to invest $12 million at its San Diego facilities in order to upgrade and expand its biomanufacturing capabilities and capacity to meet increasing customer demand for its services. This investment was made possible following the Company’s recent $32 million financing via a share placing on the London Stock Exchange.

Read more »

Abzena to pursue $5 million investment program in Bristol

Bristol PA, USA – Abzena intends to invest $5 million at its Bristol PA facility in order to increase its chemistry research and manufacturing services business for the biopharmaceutical industry. This investment was made possible following the Company’s recent $32 million financing via a share placing on the London Stock Exchange.

Read more »

AdAlta Quarterly Results and Cash Flow Statement

AdAlta Limited, an Australian based drug development company headquartered in Melbourne, announces its quarterly results.

Read more »

Clinigen and Onxeo initiate Managed Access programme for belinostat in Europe for patients with peripheral T-cell lymphoma (PTCL)

Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (‘MA’) division and Onxeo S.A (Euronext Paris, Nasdaq Copenhagen: ONXEO, ‘Onxeo’), have agreed to launch a Managed Access programme for belinostat (Beleodaq®) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral T-cell lymphoma (‘PTCL’).

Read more »

BIA Networking Breakfast - London

20 April 2017
BIA Networking Breakfast - London
London, UK

Read more »

Polyganics Announces Enrollment of the First Patient in its PROTECT NEURO Study

Groningen, The Netherlands - Polyganics, a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has enrolled the first patient in its international PROTECT NEURO study to treat and prevent symptomatic neuroma. The first patient was treated at Stanford Medicine by Catherine Curtin, MD, associate professor of surgery.

Read more »

Recce calls for Australian investment in R&D to develop new antibiotics on the back of initiatives

SYDNEY Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics to treat serious infections, today welcomed calls by the Australasian Society for Infectious Diseases and the Australian Medical Association for Australia to do more to address the growing problem of bacterial resistance to antibiotics.

Read more »

Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces that Reinhard Kandera has joined the Company as Chief Financial Officer (CFO). Effective June 1st, 2017, he will also become a member of Hookipa’s management board.

Read more »

Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Non-Executive Chairman.

Read more »

Adherium to present at Respiratory Drug Delivery Europe 2017

Melbourne, Australia - Adherium Limited (ASX: ADR, ‘Adherium’), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, will be presenting at the Respiratory Drug Delivery Europe conference 2017 (RDD Europe), being held at the Palais des Congres d'Antibes in Nice, France, from 25-28 April 2017.

Read more »

Mission Therapeutics and University of Oxford Awarded Research Grant from the Michael J. Fox Foundation

CAMBRIDGE, UK – 11 April 2017 – On World Parkinson’s day, Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that it has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Read more »

Recce Ltd - Operational Update

SYDNEY, Australia – Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, provides an update on the significant pre-clinical and operational achievements over the past few months.

Read more »

AdAlta - Research Report

MELBOURNE Australia: AdAlta Limited (ASX: 1AD) advises Patersons Securities has published updated research coverage on the Company. A copy of the 13 page research report and other recent analyst reports are available on the Company’s website: http://adalta.com.au/investors/analyst-reports/

Read more »

Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor

First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia

Lausanne, Switzerland - Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, announced today the regulatory approval of its clinical trial application to initiate a first clinical study of ASN120290 (formerly known as ASN-561), belonging to a chemically novel group of O-GlcNAcase enzyme inhibitors. Based on preclinical studies, ASN120290 has the potential to become a new treatment for dementia.

Read more »

e-Therapeutics plc Appointment of Chief Executive Officer

Oxford, UK – e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that further to the Company’s announcement on 9 January 2017, Dr. Raymond Barlow has today assumed his position as Chief Executive Officer.

Read more »

Abzena plc: Result of bookbuild

Cambridge, UK – Abzena plc (“Abzena” or the “Company”) is pleased to announce the result of the bookbuild announced earlier today (the “Placing”).

Read more »

SkinBioTherapeutics: First day of dealings

Manchester, UK - SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM at 8:00a.m. today under the ticker code SBTX and the ISIN number: GB00BF33H870.

Read more »

Abzena plc: Proposed placing of £25 million

Cambridge, UK – Abzena plc (AIM: ABZA, “Abzena” or the “Group”), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces its intention to undertake a placing to raise approximately £25 million (the “Placing”) to expand further its service offering, capacity and capabilities.

Read more »

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the developer of multi-functional Humabody® therapeutics, today announces that Dr Philip Bland-Ward has been appointed Chief Scientific Officer (CSO). The appointment will take effect in May 2017.

Read more »

Australia’s Bionic Vision Technologies Raises US$18 million (AU$23.5m) to Develop ‘Bionic Eye’ for Global Markets

MELBOURNE Australia: Retinal implant innovator Bionic Vision Technologies (BVT) today announced it had raised US$18 million (AU$23.5 million) from Hong Kong-based China Huarong International Holdings Ltd and State Path Capital Limited, to develop and commercialise its next generation devices aimed at restoring vision to the blind.

Read more »

Imanova Receives £1M Award from the MRC To Develop Early Markers of Dementia – the MIND-MAPS Study

London, UK - Following a £0.5m Medical Research Council (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss, Imanova has been awarded an additional £1m of strategic funding from the MRC for clinical evaluation of this combination of tracers in Alzheimer’s disease and Parkinson’s disease - Stage 1 of the MIND-MAPS (Molecular Imaging of Neurodegenerative Disease – Mitochondria, Associated Proteins & Synapses) programme.

Read more »

Data from large animal study shows RECCE® 327 well tolerated

Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotic, today released results from an independent study of its lead compound in large animals which showed the company’s lead asset RECCE® 327 was well tolerated with no adverse events.

Read more »

Clinigen hosts Unlicensed Medicines satellite symposium at 22nd Congress of EAHP

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services group, announces that its Idis GA division is holding a satellite symposium today on Access to Unlicensed Medicines as part of the 22nd Congress of European Association of Hospital Pharmacists (EAHP), taking place in Cannes, France.

Read more »

SkinBioTherapeutics intention to launch Initial Public Offering and list on AIM

Manchester, UK - SkinBioTherapeutics plc (“SkinBio” or the “Company”), a life science company focused on skin health, intends to seek Admission to AIM with an associated institutional and private client fundraising.

Read more »

European Group on Tumour Markers (EGTM) Updated Guidelines Recommend Agendia’s MammaPrint® Test with Highest Level 1A Clinical Evidence

Irvine, CA, USA and Amsterdam, the Netherlands - Agendia, a world leader in personalized medicine and molecular cancer diagnostics, announces that updated guidelines from the European Group on Tumour Markers (EGTM), published recently online in the European Journal of Cancer (EJC), name the MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence test as the first and currently the only multigene test of its kind deemed to have level 1A evidence for its clinical use.1

Read more »

AdAlta expands partnership with world-leading fibrosis research team at Melbourne’s The Alfred Hospital

MELBOURNE Australia: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development today announced the continuation of its collaboration with The Alfred hospital in Melbourne, Australia, and the clinical research team led by Dr Glen Westall, an expert in lung fibrosis and Idiopathic Pulmonary Fibrosis (IPF).

Read more »

Auspherix to Present Organogold Pipeline at Superbugs & Superdrugs

Stevenage, UK – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, is pleased to announce that it has been invited to present at this year’s Superbugs & Superdrugs conference in London, 20-21 March 2017.

Read more »

Mission Therapeutics Strengthens Senior Leadership Team with the Appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research

Cambridge, UK – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announced the appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research, effective 20 March 2017.

Read more »

BIA Networking Breakfast – Manchester

16 March 2017
BIA Networking Breakfast – Manchester
Alderley Park, UK

Read more »

Cell Medica: £60 million Series C financing to advance multiple cancer programmes

London, UK – Cell Medica (or ‘the Company’), a leading cellular immunotherapy company, has closed a £60 million Series C investment round with participation from existing investors Touchstone Innovations, funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management.

Read more »

Innovations invests £13.7m in £60.0m funding round in Cell Medica

Touchstone Innovations plc (AIM: IVO, ‘the Group’, ‘Innovations’) has participated in a £60.0m funding round in Cell Medica Limited (“Cell Medica” or “the Company”) committing £13.7 million to the round alongside co-investors Invesco Asset Management and Woodford Investment Management.

Read more »

Clinigen and Diurnal partner for European Managed Access programme for Infacort® and Chronocort®

Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and Diurnal Group plc (AIM: DNL, ‘Diurnal’), have partnered to launch a Managed Access programme in Europe for Infacort® to treat paediatric patients with adrenal insufficiency (AI) and Chronocort® to treat patients with congenital adrenal hyperplasia (CAH).

Read more »

Patents licensed to Synthon relating to the CD47-SIRPα pathway resist challenges in the U.S. and Europe

Nijmegen, The Netherlands – On 9 February 2017, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (USPTO) denied institution of Forty Seven Inc.’s petitions for inter partes review of the US 9,352,037 patent which was issued in May 2016.

Read more »

Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

Stevenage, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £895,000 from the Biomedical Catalyst for initiation of a research programme with a novel approach to the treatment of dementia. An investment of £400,000 from the Dementia Discovery Fund (“DDF”) will also be used to pursue this highly novel approach to dementia treatment.

Read more »

Clinigen Group plc: STRONG H1 PERFORMANCE WITH ADJUSTED EPS UP 31%*

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the global pharmaceuticals and services company, today publishes its half year results for the six months ended 31 December 2016.

Read more »

Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval

Cambridge, UK – Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received US Food and Drug Administration (FDA) marketing approval for Kisqali® (ribociclib, formerly known as LEE011) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced (metastatic) breast cancer.

Read more »

First-in-class Fycompa® (perampanel) approved in South Africa for partial-onset seizures

Clinigen Group plc - Eisai is pleased to announce that perampanel has been approved in South Africa for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.1 Perampanel is the first anti-epileptic drug to be approved in South Africa in recent years.

Read more »

German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence

Irvine, CA, USA and Amsterdam, the Netherlands - Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the company’s MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence test is now included with the highest medical evidence level 1A in the latest version of AGO (German Association of Gynecological Oncology) guidelines for the care of breast cancer patients in Germany.

Read more »

SACHS 10th Annual European Life Sciences CEO Forum & Exhibition

6 – 7 March 2017
10th Annual European Life Sciences CEO Forum & Exhibition
Zurich, Switzerland

Read more »

DNAe Appoints International Infectious Disease Experts to its Newly Formed Clinical Advisory Board

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the formation of its clinical advisory board (CAB). The CAB, with founding members Professor Paul Dark, Professor Angela Caliendo, Professor Stephan Harbarth and Professor Romney Humphries, brings together US and European experts to provide strategic guidance for the clinical development of DNAe’s diagnostic platform, LiDia™, and its accompanying range of tests for different clinical applications.

Read more »

‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase II clinical trial.

Read more »

Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Vienna, Austria - Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and Development. The appointment is effective from today.

Read more »

Staten Biotechnology exercises option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia from argenx N.V.

Nijmegen, The Netherlands – Staten Biotechnology, a company focused on the treatment of dyslipidemia and reduction of cardiovascular mortality today announced that it has exercised an exclusive option to license ARGX-116 (STT-5058), an anti-ApoC3 SIMPLE Antibody from argenx N.V.

Read more »

One Nucleus: Leadership Seminar: Microbiome – Research to Revenue

2 March 2017
One Nucleus: Leadership Seminar: Microbiome – Research to Revenue
Norwich Research Park, UK

Read more »

Synthon enters worldwide exclusive license and collaboration with Sanquin for immuno-oncology therapeutic leads modulating the CD47-SIRPα pathway

Nijmegen and Amsterdam, The Netherlands - Synthon Biopharmaceuticals BV, an international biopharmaceutical company that is focused on developing new molecular entities for treating cancer and autoimmune diseases, today announced that it has entered a license and collaboration agreement for the development of novel immuno-oncology antibodies with Sanquin Blood Supply Foundation (‘Sanquin’), Amsterdam.

Read more »

Abzena plc: Medical Research Council grant awarded to collaboration group developing novel autoimmune therapy

Cambridge and London, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products and UCL (University College London), one of the world’s leading multidisciplinary universities, supported by UCL Business, the technology commercialisation company of UCL, announce that a research group from UCL’s Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to progress the development of a novel treatment for anti-phospholipid syndrome (APS) which uses Abzena’s proprietary conjugation technology.

Read more »

Whatman™ EasiCollect™+ System for simple, reliable buccal sample collection and storage

EasiCollect™ + System from GE Healthcare’s Life Sciences business addresses the difficulties of buccal cell collection for forensic analysis with an updated design which increases usability and first pass success rates. Providing consistent sample transfer to FTA™ cards, EasiCollect+ simplifies the collection and storage of DNA for genetic analysis in forensics, human identification and SNP genotyping.

Read more »

Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs

LONDON, BOSTON, TOKYO  – The steady and inexorable growth of the orphan drug market remains one of the prominent themes in the fourth edition of the EvaluatePharma Orphan Drug Report 2017. What has changed in the last 12 months according to the report is the increased scrutiny of the price of these lifesaving products.

Read more »

Halaven® (eribulin) launches in South Africa for the treatment of women with advanced breast cancer

Halaven® (eribulin) is now available in South Africa for the treatment of women with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for their advanced disease. Prior therapy should have included an anthracycline and a taxane, unless patients were not suitable for these treatments.

Read more »

Congenica raises £8M ($10M) in Series B financing round to drive international expansion of its genome analysis business

CAMBRIDGE, UK - Congenica, a leading provider of clinical genome analysis technology, announced today that it has raised £8m ($10m) in its Series B financing round. Existing investors, Cambridge Innovation Capital plc (CIC) and Amadeus Capital Partners (Amadeus) participated alongside new investor, Parkwalk Advisors (Parkwalk).

Read more »

Recce Releases Microscopy Images of its Synthetic Antibiotic in Action Destroying Bacteria

SYDNEY, Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotic, today released images taken of RECCE® 327 destroying Escherichia coli Gram-negative bacteria, the superbug form of which has been declared by the US Centres for Disease Control and Prevention as an urgent threat to world health.

Read more »

AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman

San Diego, U.S. – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board (SAB) and the appointment of Timothy K. Lu, M.D., Ph.D., as Chairman of the SAB. Dr. Lu heads the Massachusetts Institute of Technology’s (MIT) Synthetic Biology Group in the Research Laboratory of Electronics, where he applies proprietary engineering techniques to biological systems, including bacteriophages, to address global concerns such as the growing incidence of antibiotic resistance.

Read more »

20 years ago Instinctif Partner’s Sue Charles introduced a now famous sheep to the world

On this Day - 22 Feb 1997

20 years ago Instinctif Partner’s Sue Charles introduced a now famous sheep to the world

In February 1997, via a publication in Nature, scientists in Scotland announced the birth of the world's first successfully cloned mammal, and it was Instinctif Partners Managing Partner Sue Charles, who led the PR effort to introduce ‘Dolly the sheep’ to the world.

Read more »

Recce to suspend anti-cancer program and focus on commercialising synthetic lead compound against resistant bacteria and viruses

SYDNEY, Australia: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of antibiotics, today announced it would halt further investment in its anti-cancer program and focus on commercialising its lead synthetic compound RECCE® 327 to address drug resistant bacteria and viruses.

Read more »

Funding of four initial projects and operational update

Stevenage: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, has invested in and launched the first of its drug discovery programmes in collaboration with academics at each of its partner universities.

Read more »

DNAe announces opening of US facility, expansion of operations and launches product brand as it prepares for commercialization

London, UK and Carlsbad, CA, USA – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the opening of its new US facility in preparation for commercializing its first product. DNAe also announces its new brand identity.

Read more »

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016

LONDON, BOSTON, SAN FRANCISCO, TOKYO – For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released today as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.

Read more »

Innovations portfolio company Cell Medica granted FDA Fast Track designation for lead oncology product

Touchstone Innovations plc (AIM: IVO, ‘the Group’, ‘Innovations’) is pleased to note today’s announcement by portfolio company Cell Medica (the ‘Company’) that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead oncology product (CMD-003) for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein Barr virus (EBV).

Read more »

Lead cancer immunotherapy candidate receives FDA fast track designation

London, UK and Houston, TX, US - Cell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product CMD-003 for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein Barr virus (EBV).

Read more »

Abzena plc: Antibody manufacturing development agreement signed with UCL

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a manufacturing agreement with University College London (‘UCL’), one of the world’s leading universities. Under the agreement, Abzena will manufacture Magacizumab, an antibody created using the ‘Abzena inside’ Composite Human Antibody™ technology.

Read more »

Abzena plc: Trading and business update

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides the following business update for the period to 20 February 2017.

Read more »

Polyganics’ “STOP NEUROMA” Study Interim Data Shows Reduction in Pain

Groningen, The Netherlands – Polyganics, a privately held medical technology company, announced today that interim results show a sharp improvement in pain reduction observed across patients currently enrolled within the “STOP NEUROMA” study.

Read more »

Asthma UK’s ‘Smart Asthma’ report highlights opportunity to improve asthma care through connected health

Melbourne, Australia - Adherium Limited (ASX: ADR, ‘Adherium’), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, welcomes the recommendations highlighted in Asthma UK’s report on the use of connected devices in managing asthma, published today. ‘Smart Asthma for the UK; Real world implementation of connected devices to reduce asthma attacks’, highlights the opportunities for healthcare providers to positively influence clinical and economic outcomes for asthma care in the UK through the use of connected devices and improved technology infrastructure.

Read more »

Trod Medical Receives US Patent Allowance for Prostate Focal Therapy EncageTM Device

Leuven, Belgium – Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office (USPTO), entitled  “Method of percutaneous localized or focal treatment of prostate lesions using radio frequency”, with patent ID US 20110288541 A1.

Read more »

Biotech and Money London 2017

7 – 8 February 2017
Biotech and Money London
London, UK

Read more »

Forbion Invests in Prexton Therapeutics’ EUR 29 million (USD 31 million) Series B Financing

Naarden, The Netherlands – Forbion Capital Partners (“Forbion”), one of the leading Dutch Venture Capital firms investing in world-class healthcare technologies, today announced the closing of a Series B financing round of EUR 29 million (USD 31 million) for Prexton Therapeutics (Prexton). Prexton is a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions.

Read more »

Atomo Diagnostics receives further international financing

SYDNEY, Australia: Medical device innovator Atomo Diagnostics today announced it had received US$1 million (A$1.31 million, C$1.32 million) in financing from Grand Challenges Canada to support its continued business operations.

Read more »

Ampliphi Biosciences to Present at the 19th Annual BIO CEO and Investor Conference

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that CEO M. Scott Salka will present a company overview at the 19th Annual BIO CEO and Investor Conference on Monday, February 13, 2017 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time).  The conference is being held at the Waldorf Astoria New York hotel in New York City.

Read more »

UV-Cap GmbH & Co KG acquires Scil Proteins GmbH Scil Proteins GmbH becomes Navigo Proteins GmbH

Halle (Saale), Germany – Scil Proteins GmbH, the expert protein engineering company for affinity ligands and targeted carriers, today announced that UV-Cap GmbH & Co KG, Ravensburg, has acquired 100% of the shares of Scil Proteins from Bionet Ventures GmbH, Munich. The Company will be renamed to Navigo Proteins GmbH. All staff and management will be retained.

Read more »

Arven Pharmaceuticals selects GE Healthcare’s FlexFactory to improve Turkish and regional access to biopharmaceuticals

CHALFONT ST. GILES, UK and ISTANBUL, TURKEY – Arven Pharmaceuticals, a Toksoz Group Company, has selected GE Healthcare’s FlexFactory manufacturing platform to expand production capacity at its facility in Kirklareli, Turkey. With this expanded capacity, Arven will support local healthcare needs by bringing biopharmaceuticals to the Turkish and surrounding markets faster, whilst also opening up European markets through the FlexFactory’s proven track record in meeting global regulations and quality standards.

Read more »

Dimerix key patent allowed in Japan for use of lead drug candidate in the treatment of kidney disease

MELBOURNE, Australia: Dimerix Limited (ASX: DXB), a clinical stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced the Japanese Patent Office has allowed a key patent covering the use of its lead compound DMX-200 for the treatment of kidney disease.

Read more »

AdAlta’s Q4 Statement – Delivering on Key Milestones and Progress of AD-114 Lead Fibrosis Product Towards the Clinic

AdAlta continues to meet its commercial and development milestones and is making excellent progress towards its stated goal of initiating Phase I human clinical trials for its lead candidate AD-114 as a therapy for the unmet medical need of idiopathic pulmonary fibrosis (IPF), including securing Orphan Drug Designation from the FDA. The Company is also developing AD-114 for Non-alcoholic steatohepatitis (NASH), a pandemic, metabolic disease which has both inflammatory and fibrotic components.

Read more »

AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the appointment of Igor P. Bilinsky, Ph.D., as its Senior Vice President and Chief Operating Officer, effective January 30, 2017.  Dr. Bilinsky brings to AmpliPhi nearly two decades of experience as a life sciences company executive and consultant, serving public and private companies.  He succeeds Wendy S. Johnson, who served as AmpliPhi’s interim COO since September 2014 and continues to serve on AmpliPhi’s board of directors.

Read more »

Agendia Co-Founder Laura van ‘t Veer Wins European Cancer Organization Clinical Research Award

IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, congratulates its co-founder and Chief Research Officer, Professor Laura van ‘t Veer, Ph.D., on winning the European Cancer Organization’s (ECCO) Clinical Research Award for innovation in breast cancer diagnosis, and the development of diagnostics for implementation in daily clinical practice, including treatment guidelines, regulatory policies and reimbursement.

Read more »

BIA Gala Dinner 2017

26 January 2017
BIA Gala Dinner
London, UK

Read more »

Innovative Wellbeing Company Skinjay Receives €3.5M from Seventure Partner’s Health for Life Capital

Paris, France - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that from its Health for Life Capital investment vehicle it has invested €3.5 million in Skinjay.

Read more »

Evaluate: The Value of Outliers in Consensus Forecasting

LONDON, BOSTON, SAN FRANCISCO, TOKYO – Life science market intelligence firm Evaluate Ltd today released the first of a series of reports focused on Forecasting Excellence with an aim to improve the ability of the pharmaceutical industry to deploy capital more efficiently.

Read more »

Dimerix Raises AU$2 million to Advance Clinical Program

Dimerix Limited (“Dimerix” or “the Company”) advises that it has received commitments for a placement to raise AU$2,000,000 (before costs) (Placement). 333,333,333 new shares will be issued to sophisticated and professional investors under the Placement at an issue price of AU$0.006 per share. Westar Capital Ltd acted as Lead Manager to the offer.

Read more »

HY trading update: strong H1 performance with gross profit up 34%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides a trading update for the six months ended 31 December 2016.

Read more »

Abzena signs new ThioBridge™ licence agreement

Cambridge, UK – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement with a San Diego-based biopharmaceutical company for Abzena’s novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology.

Read more »

AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease

MELBOURNE Australia - AdAlta Limited (ASX: 1AD), today announced it has received Orphan Drug Designation from the United States Food and Drug Administration (FDA) for AD-114, a novel first-in-class drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF).

Read more »

Recce’s lead compound reduces illness in mice infected by resistant E. coli bacteria

SYDNEY: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics to treat serious infections, today announced encouraging early results for the company's lead product candidate RECCE® 327 as a potential treatment against Carbapenem resistant Gram-negative (CRE) Escherichia coli (CRE E. coli).

Read more »

Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance

Joins trade associations and over 100 pharmaceutical, biotech and diagnostic companies to call for collective action and government support to tackle crisis

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections, has signed The Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR), announced today at the World Economic Forum Annual Meeting in Davos, Switzerland.
 

Read more »

Clinigen initiates U.S. Managed Access program for TESARO’s niraparib for patients with ovarian cancer

Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access (MA) division has partnered with TESARO Inc. (NASDAQ: TSRO), to launch a Managed Access program (also known as an expanded access program (EAP)) for the investigational PARP 1/2 inhibitor, niraparib.

Read more »

35th J.P. Morgan Healthcare Conference & 9th Annual Biotech Showcase

9 – 11 January 2017
35th J.P. Morgan Healthcare Conference & 9th Annual Biotech Showcase
San Francisco, US

Read more »

Instinctif Partners awarded silver in the PR Week UK Best Places to Work Awards 2017

Instinctif Partners has been awarded silver in the large consultancy category by PR Week for Best Places to Work

These awards recognise those UK-based consultancies and in-house comms departments that go the extra mile to offer a superb working environment and progressive practices in the workplace, whether it's around training, mentoring, pay, maternity and paternity issues, or a host of other areas.

Read more »

NICE acknowledges Smartinhaler™ technology can improve adherence to asthma medication

NICE (the National Institute for Clinical Excellence) has today issued a Medtech Innovation Briefing on Smartinhaler™, Adherium Limited’s (ASX: ADR) innovative digital inhaler technology platform, which has been proven to increase patient adherence to asthma medication, reduce hospital visits and time needed off school or work over the current standard care.

Read more »

Adherium appoints digital health pioneer to lead European business development

Digital health veteran to join expanding global team

Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. John Tarplee stepped down from the role at the end of December 2016 to pursue a new venture.

Read more »

Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

Demonstrated dose dependent changes in Mismatch Negativity latency in healthy volunteers; Phase Ib Ketamine challenge study initiated in Manchester.

London, UK - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced positive findings from a Phase Ia clinical trial of AUT00206, a first-in-class Kv3 modulator in development for the treatment of schizophrenia, as well as the start of the first of two Phase Ib studies with the molecule.

Read more »

Clinigen and Cumberland Pharmaceuticals enter exclusive U.S. commercialisation agreement for Totect®

Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company and Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX, ‘Cumberland’), a U.S. specialty pharmaceutical company announce an exclusive agreement to commercialise the oncology support drug, Totect® (dexrazoxane hydrochloride) in the U.S.

Read more »

Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave® as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections

Vienna, Austria - Hookipa Biotech AG, an immunotherapy company developing next-generation cancer immune therapeutics and vaccines based on the Company's proprietary arenavirus vector platforms, announces publication in the January 2017 issue of the peer-reviewed journal Clinical and Vaccine Immunology, of data confirming the potential of Hookipa’s HB-101 Vaxwave® to provide an effective and novel bivalent vaccine that confers better protection against congenital (maternal transmission) cytomegalovirus infection in the gold standard animal model, the guinea pig model, in reducing pup mortality.

Read more »

AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential

MELBOURNE Australia, 9 January, 2017 - AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development today announced additional positive pre-clinical data for its lead drug candidate AD-114, a novel first-in-class drug candidate being developed to treat fibrosis, a condition prevalent in 45 to 50 per cent of all diseases.

Read more »

Appointment of Amgen Executive Director as Chief Executive

Oxford, UK – e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it has appointed Dr. Raymond Barlow as Chief Executive Officer. Dr. Barlow will take up the role on or before 1 May 2017, at which point he will be appointed to the e-Therapeutics Board of Directors.

Read more »

Seventure Partners Life Sciences, Microbiome Investing: Update for September – December 2016

Paris, France – Seventure Partners (the Company), one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for September – December 2016.

Read more »

Auspherix Provides Update on its New Class of Organogold Antibiotics

Stevenage, UK – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today provided an update on its organogold chemistry platform and its pipeline of compounds.

Read more »

Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies

Santa Monica, CA and Alachua, FL – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis.

Read more »

Xigen’s Brimapitide, an innovative JNK inhibitor, delivers positive Phase II results in inflammatory eye disease

Geneva, Switzerland – Xigen, a Swiss Company developing therapeutic peptides for the treatment of inflammatory diseases announces today the online publication of successful Phase II results for its lead compound Brimapitide (XG-102) in the American Journal of Ophthalmology.

Read more »

Change of name to Touchstone Innovations plc and change of registered office

Imperial Innovations Group plc (AIM: IVO, ‘the Company’) announces that further to the shareholder approval received at its AGM on 21 November 2016, the change of the Company's  name to Touchstone Innovations plc took effect on 4 January 2017.

Read more »

Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients

SAN DIEGO – AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Peter-John Wormald, MD, Professor of Otolaryngology Head & Neck Surgery at the University of Adelaide, commented on the favorable results from the Phase 1 trial of AmpliPhi’s AB-SA01 in patients with chronic rhinosinusitis (CRS).

Read more »

Clinical Network Services (CNS) UK Announces the Appointment of Dr Martin Moxham as Principal Regulatory Consultant

Brisbane, Australia - Clinical Network Services (CNS), an integrated service group focused on clinical product development and headquartered in Australia with offices in New Zealand, the UK and the USA, has announced the appointment of Martin Moxham as Principal Regulatory Consultant for Europe from 1 January 2017.

Read more »